CERo Therapeutics Holdings, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CERO | KAPA | CRIS | CVM | UKJ0.F | ATRA | |
|---|---|---|---|---|---|---|
| Market cap | 318.76K | 1.66M | 7.41M | 24.27M | 6.29M | 84.02M |
| P/E (TTM) | 0.0 | — | 0.8 | — | 0.0 | — |
| Forward P/E | 0.0 | -0.1 | -0.2 | -0.2 | — | 5.4 |
| Price/book | 0.0 | 0.4 | 0.5 | 2.2 | 0.3 | -2.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −95.65% | −91.95% | −96.20% | −79.22% | −98.81% | −29.19% |
| Today | −11.00% | −3.03% | +55.48% | −2.13% | +21.05% | +2.07% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CERO news ›CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms ... CERo Therapeutics Announces…
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
SRX expects capital to be raised directly into the subsidiary without diluting existing SRX Global shareholders. SRX disclosed a senior secured debt investment in CERo, the same company now covered by the acquisition agreement. 24h Move is…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.